In April 2009, a new influenza strain − H1N1 'swine flu' − was identified in Mexico with an apparent high case fatality rate (about 5%). As H1N1 spread rapidly throughout the world it caused not only a 'pandemic' but also widespread fear. However, overall, swine flu has been associated with fewer deaths (case fatality rate < 0.01%) than seasonal influenza (case fatality rate < 0.1% approx.), 1 and is of low virulence. While younger people were disproportionately infected by swine flu, it was people aged 50-60 years who had more frequent serious illness in terms of admissions to intensive care units and deaths. 2−4 In the 2009 Australian winter, swine flu's associated mortality rate was 0.9 per 100 000 people. In those under 40 years with no risk factors, the mortality rate was less than one per million. 3 While there were some differences (for example pregnant women), the overall effects of this virus as judged by absenteeism, hospitalisations and deaths were similar to those of previous seasonal influenza strains. 2−4 While swine flu is a 'new' virus, it is an H1N1 virus, strains of which have been circulating since 1918. Not surprisingly, many people have pre-existing immunity. Most people over 65 years appear to be immune, as reflected by their low infection rates.
In an Australian H1N1 vaccine trial of adults (aged 18-65 years), 27% had protective antibody concentrations and 62% had detectable pre-existing antibodies. 5 A problem with this vaccine and other influenza vaccines is that there are relatively few well-designed, large randomised studies. 5, 7 The efficacy of seasonal inactivated parenteral vaccines in preventing influenza in healthy adults varies from 50% to 80%. 7 The often quoted efficacy for protection from all-cause mortality with seasonal influenza vaccines is around 50%. However, those in vaccinated groups frequently have fewer comorbidities than those in non-vaccinated groups. A recent Californian study looked at over 100 000 deaths over nine years 8 and showed that the decrease in all-cause mortality attributable to seasonal influenza vaccine was 4.6%.
The reason these issues are important is that we do not have robust data on which to make proper decisions on the costeffectiveness of any mass vaccine programs. In young people without risk factors, the rates of death and complications last winter from swine flu were very low and are similar to the risk of serious vaccine-associated adverse effects such as GuillainBarré syndrome and anaphylaxis. Around 50% of people who received the H1N1 vaccine in the Australian trial had mild to moderate systemic adverse effects and 1.7% had (solicited) systemic adverse effects recorded as severe. 5 In children, 20% had moderate to severe systemic adverse effects after receiving a single 15 microgram dose of vaccine. 9 It is very important that we make sure we do more good than harm with any vaccine. Thus, we need a large cohort of people (tens of thousands) followed prospectively so that we can accurately know what are the percentages of people with adverse effects in the postmarketing period. We also need a robust system to accurately detect the very rare but serious adverse effects. otherwise we risk repeating the mistakes made in the 1976 USA swine flu vaccine program. 6 The disproportionate fear generated by the swine flu virus has caused many decisions to be made that in retrospect were inappropriate. We need to learn from our experiences and more importantly ensure that well-designed, large, prospective long-term studies are done so we can answer basic questions on the true safety and efficacy of influenza vaccines. This is not only in the elderly but also in groups proposed for routine seasonal influenza campaigns such as children and pregnant women. We need these types of data before embarking on further mass immunisation programs, particularly if done during periods with likely low infection rates (that is, summer) using multidose vials.
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